semaglutide Semaglutide Drug Names : Ozempic (for T2DM) - injectable Wegovy (for weight management) - injectable Rybelsus (oral) - 1st oral GLP-1 agonist (FDA approved 9/20/19) Drug Category : GLP-1 receptor agonist, hypoglycemic Synthetic peptide analog of GLP-1 Mechanism of Action: Synthetic peptide that is chemically identical to GLP-1, except for three amino acid substitutions and modifications at positions 8, 26 & 34 (Figure 1) that prevent chemical breakdown by DPP-4, and increase binding to albumin
Additionally, Semaglutide is stipulated as an accompaniment to regular exercise and diet for chronic weight management in adults suffering from obesity or overweight with no less than one weight-related symptomatology such as high blood pressure, increased cholesterol levels, and type 2 diabetes
J., Mezquita-Raya, P., Carretero-Gmez, J., et al
Side effects are most common when you first start using the medication or increase the dose, and higher doses of both drugs can lead to a higher risk of side effects
Wegovy is indicated for people ages 12 years and older who have: A BMI of 30 kg/m 2 or higher A BMI of 27 kg/m 2 to 29.9 kg/m 2 and at least one weight-related comorbidity , such as high blood pressure, type 2 diabetes, or obstructive sleep apnea Wegovy is also indicated to reduce the risk of major cardiovascular events , such as heart attack or stroke, in people who have obesity or overweight
Dizziness occurs in some users, particularly during the first weeks
